瑞舒伐他汀联合曲美他嗪治疗慢性心力衰竭患者的疗效及对血清炎性因子及血浆内皮素水平的影响  

Efficacy of rosuvastatin combined with trimetazidine in the treatment of chronic heart failure and its affect on the levels of serum inflammatory factors and plasma endothelin

作　　者：崔青丽 

机构地区：[1]潢川县人民医院心内科,河南省潢川县465150

出　　处：《内科》2017年第4期468-470,共3页Internal Medicine

摘　　要：目的探讨瑞舒伐他汀联合曲美他嗪治疗慢性心力衰竭(CHF)患者的疗效及对血清炎性因子及血浆内皮素水平的影响。方法选取2013年2月至2016年7月在潢川县人民医院住院治疗的CHF患者92例为研究对象,采用随机数表法分为观察组和对照组,每组46例。两组患者均给予CHF常规治疗,在此基础上对照组患者采用曲美他嗪治疗,观察组患者使用曲美他嗪联合瑞舒伐他汀治疗。比较两组患者的临床疗效及不良反应发生情况;检测比较两组患者治疗前后血清炎性因子、血浆内皮素(ET)、B型脑钠肽(BNP)水平的变化情况。结果观察组患者治疗总有效率(93.48%)显著高于对照组(78.26%),差异有统计学意义(P<0.05)。治疗后,观察组患者TNF-α、IL-6、IL-17水平均显著低于对照组,差异有统计学意义(P<0.05);观察组患者ET及BNP水平均显著低于对照组,差异有统计学意义(P<0.01)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论在常规治疗的基础上,瑞舒伐他汀联合曲美他嗪治疗可有效减轻CHF患者机体炎症反应,降低血浆ET及BNP水平,临床效果显著,安全性良好。Objective To investigate the efficacy of rosuvastatin combined with trimetazidine in the treatment of chronic heart failure （CHF） and its affect on the levels of serum inflammatory factors and plasma endothelin. Methods A total of 92 CHF patients who were hospitalized in Huangehuan County People＇s Hospital from February 2013 to July 2016 were selected and divided into observation group and control group according to the random number table, with 46 cases in each group. Both groups were treated with conventional treatment, and the control group was treated with trimetazidine on the basis of conventional treatment, while the observation group was treated with trimetazidine and rosuvastatin on the basis of conventional treatment. The clinical efficacy and adverse reaction were compared between the two groups; the levels of serum inflammatory cytokines, plasma endothelin （ET） and B - type brain natriuretic peptide （BNP） of the two groups were measured before and after treatment. Results The total effective rate of the observation group （93.48%） was significantly higher than that in the control group （78.26% , P 〈0.05）. After treatment, the levels of TNF-α, IL-6, IL-17, ET and BNP in observation group were significantly lower than those in the control group （ P 〈 0.05 ）. No significant difference was found between two groups in adverse reaction （ P 〉 0.05 ）. Conclusions On the basis of conventional therapy, rosuvastatin combined with trimetazidine on the treatment of patients with CHF can effectively alleviate inflammation, reduce the levels of serum ET and BNP, and the effect is significant, and have good safety.

关 键 词：慢性心力衰竭 治疗 瑞舒伐他汀 曲美他嗪 血清炎性因子 血浆内皮素 B型脑钠肽 

分 类 号：R541.6[医药卫生—心血管疾病]